IHC custom assay

Immunohistochemistry (IHC), also known as immunohistochemistry and cytochemistry, uses the principles of immunology to apply antigen-antibody reactions to histocytochemistry to further increase sensitivity through cascade amplification. Subsequently, the chromogenic reagent (fluorescein, enzyme, metal ion, isotope) of the labeled antibody is colored by chemical reaction, so as to determine the localization, qualitative and relative quantitative research of various gene products such as antigen (protein polypeptide, enzyme) in tissue cells .

In pathology, it can be used for the diagnosis and differential diagnosis of tumors of different origins that are difficult to diagnose by HE staining.

The basic principle is to apply the reaction of "antigen-antibody complex" after contact between antigen and antibody to detect antigen (or antibody) in tissue or cells.

Liwen CAP Central Laboratory has established a professional technical team with Professor Zhu Minghua, Deputy Director of the Clinical Pathology Quality Evaluation Center of the Ministry of Health as the core, to supervise and guide the whole process of IHC testing service process and testing quality.

In addition to conventional tumor IHC detection indicators such as HER2, dMMR, PD-L1, ER, PR, etc., Liwen Biotech also provides immunohistochemical indicators for innovative drugs such as Claudin 18.2, MSLN related to CART therapy, and TROP2 related to ADC conjugate therapy. Customized testing services are also available.